By Adrian Burton, Special to DG News, LISBON, PORTUGAL — May 15, 2002 — A pan-European study strongly suggests that oral strontium ranelate is a safe treatment for women with vertebral osteoporosis and that it has a unique mechanism of action. The findings were reported at the International Osteoporosis Foundation’s World Congress on Osteoporosis. Osteoporosis occurs because bone formation is reduced while its breakdown increases. “If we tried to define the ideal osteoporotic drug, it would increase bone formation and decrease bone resorption,” said Pierre Meunier, Prof. of Medicine at the Edouard Herriot Hospital, Lyon, France. “We have drugs capable of doing one or the other, but if we could find one capable of doing both, that would be nice.” The results of this study show strontium ranelate may be such a drug. The dose-ranging STRATOS study had already confirmed that a daily dose of two g is optimal in increasing lumbar bone mineral density (BMD). Now, a three year, randomized, double blind, placebo-controlled phase III study performed in 12 European countries has shown that this dose is capable of drastically reducing the relative risk of new vertebral fractures. The 1649 study subjects were divided into two parallel groups of mean age 69.7 (7.3) years and lumbar BMD 0.73 (0.12). Of these, 87.5 percent had at least one vertebral fracture. Patients received either the above dose of strontium ranelate or a placebo. All received concurrent calcium and vitamin D supplements.
האם המהפכה הטיפולית בהשמנת יתר תפרוץ את חומת הכלכלה? פרופ' רז ופרופ' שטרן
לפניכם הרצאה ודיון שהתקיים בין פרופ’ איתמר רז ופרופ’ נפתלי שטרן בנושא השפעות החידושים הטיפוליים בתחום ההשמנה.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!